▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
April 26, 2024

Market Now

Antrogen obtains Hong Kong patent for fistulas-treating stem cell composition

  • PUBLISHED :June 14, 2017 - 17:43
  • UPDATED :June 14, 2017 - 17:43
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print
[DISCLOSURE] Anterogen (065660) announced on June 14 that its autologous and allogenic adipose-derived stromal stem cell composition for treating fistulas has been granted a patent in Hong Kong. 

By Hwang You-mee (theinvestor@heraldcorp.com)

BACK TO LIST TOP

EDITOR'S PICKS

  • 인스타그램
Herald Corporation |CEO : Choi Jin-Young |Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea |Title : The Investor |Date of registration : 2016.06.21 |Date of issue : 2016.06.21
Publisher. Editor : Choi Jin-Young |Chief Privacy Officer & Juvenile Protection Manager : Choi He-suk |T +82-2-727-0021 |E investor@heraldcorp.com
FAMILY SITE GO

Company Registration No. 104-81-06004 |Mail-Order Business Registration 2016 - Seoul Yongsan - 00590 |Business info |Gov’t registration No. Seoul 아04099